ConductScience.org, home

Comparison · NCT00141102-eea04678

Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin. Trial comparisons, record NCT00141102-eea04678. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00141102-eea04678

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.02060.01540.0275wilson
Risk in group 20.05680.04780.0673wilson
Risk difference, group 1 minus group 2-0.0362-0.0479-0.0249newcombe hybrid score
Risk ratio, group 1 over group 20.3630.2590.508log
Odds ratio, group 1 over group 20.350.2470.495log
Number needed to treat, for one fewer participant with the outcome on Celecoxib than on Oral Diclofenac Plus Omeprazole27.720.940.2from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Celecoxib200 mg BID plus omeprazole placebo and diclofenac SR placebo452,184OG000
Group 2Oral Diclofenac Plus OmeprazoleOral diclofenac SR (75 mg BID) plus omeprazole (20 mg once daily \[QD\]) and celecoxib placebo.1232,167OG001

Outcome

Type
SECONDARY
Title
Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin
Description
A clinically significant decrease from baseline was defined as a fall in hematocrit \> = 10 percentage points and/or hemoglobin \> = 2 g/dL.
Time frame
6 month treatment duration
Population
Safety population. Number of Participants Analyzed = number of subjects with analyzable data.

Source ClinicalTrials.gov

Trial

Title
Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis
NCT number
NCT00141102
Phases
PHASE4
Conditions
Osteoarthritis, Arthritis, Rheumatoid
Interventions
Celecoxib, Diclofenac + Omeprazole
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Results first posted
2010-06-11

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00141102-eea04678